From 17 May announcement:
Saliva Use Case
The laboratory validation of the saliva samples is currently underway. Pending analysis and results of the saliva samples, an updated CE regulatory submission will be made to amend the Instruction For Use (IFU) of the current EuGeni SARS-CoV-2 ART to include oral saliva sampling. The test and all components remain the same. AnteoTech remains on track to submit the update to the CE Mark in June 2021, pending results.
Ann: AnteoTech raises $8.0m in strongly supported SPP, page-75
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.79M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 2.0¢ | $3.965K | 195.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1417631 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 95237 | 1 |
View Market Depth
| Last trade - 14.20pm 11/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |